Stockscreener 앱 받기
100.82
0.61%
0.61
시간 외 거래:
100.82
전일 마감가:
$100.21
열려 있는:
$99.78
하루 거래량:
492.57K
Relative Volume:
0.78
시가총액:
$6.70B
수익:
$136.86M
순이익/손실:
$-168.69M
주가수익비율:
-35.88
EPS:
-2.81
순현금흐름:
$-113.49M
1주 성능:
+1.82%
1개월 성능:
+0.55%
6개월 성능:
+74.34%
1년 성능:
+110.17%
1일 변동 폭
$97.97
$102.92
1주일 범위
$96.30
$102.92
52주 변동 폭
$45.91
$106.52
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
RYTM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
100.82 | 6.66B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Long term hold vs stop loss in Rhythm Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Tips - newser.com
What analysts say about Rhythm Pharmaceuticals Inc 1RV stockVolatility Index Analysis & Minimize Portfolio Damage with Warnings - earlytimes.in
Using RSI to spot recovery in Rhythm Pharmaceuticals Inc.2025 Trade Ideas & Real-Time Stock Movement Alerts - newser.com
Should you hold or exit Rhythm Pharmaceuticals Inc. now2025 Top Gainers & Trade Opportunity Analysis - newser.com
What indicators show strength in Rhythm Pharmaceuticals Inc.Weekly Profit Recap & Capital Efficiency Focused Ideas - newser.com
Leo Wealth LLC Has $850,000 Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Is Rhythm Pharmaceuticals Inc. (1RV) stock a safe buy pre earningsCEO Change & Consistent Growth Equity Picks - newser.com
Rhythm Pharma Stock Gears Up For Its Next Move - inkl
How to recover losses in Rhythm Pharmaceuticals Inc. stock2025 Market Outlook & Fast Exit and Entry Strategy Plans - newser.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Is Rhythm Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Key Lessons & Low Risk High Win Rate Stock Picks - newser.com
Why Rhythm Pharmaceuticals Inc. (1RV) stock could be next leaderWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Rhythm Pharmaceuticals Inc a good long term investmentEconomic Indicators Overview & Low Risk Capital Growth Plans - earlytimes.in
Is Rhythm Pharmaceuticals Inc. (1RV) stock supported by free cash flowIndex Update & Low Volatility Stock Recommendations - newser.com
What momentum shifts mean for Rhythm Pharmaceuticals Inc.July 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
Will Rhythm Pharmaceuticals Inc. rebound enough to break evenRecession Risk & Verified High Yield Trade Plans - newser.com
Using data tools to time your Rhythm Pharmaceuticals Inc. exitJuly 2025 Macro Moves & Intraday High Probability Alerts - newser.com
Is Rhythm Pharmaceuticals Inc. stock cheap at current valuationWeekly Trading Summary & Weekly Stock Breakout Alerts - newser.com
Institutional scanner results for Rhythm Pharmaceuticals Inc.Market Volume Report & Fast Exit/Entry Strategy Plans - newser.com
Is Rhythm Pharmaceuticals Inc. stock dividend yield sustainableMarket Performance Recap & Fast Gaining Stock Strategy Reports - newser.com
Should You Expect Robust Growth Potential for Rhythm Pharmaceuticals (RYTM) Ahead? - Yahoo Finance
Is Rhythm Pharmaceuticals Inc. (1RV) stock a buy before earnings resultsJuly 2025 News Drivers & Intraday High Probability Setup Alerts - newser.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Bardet-Biedl Syndrome Pipeline 2025: Pioneering Clinical Developments by 8+ Global Leaders – DelveInsight | Featuring Rhythm Pharmaceuticals - Barchart.com
Rhythm Pharmaceuticals stock price target raised by H.C. Wainwright to $110 - Investing.com Canada
HC Wainwright & Co. Maintains Rhythm Pharmaceuticals (RYTM) Buy Recommendation - Nasdaq
RYTM: HC Wainwright Raises Price Target, Maintains Buy Rating | - GuruFocus
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Exploring an 18.64% Potential Upside in the Rare Disease Biotech Space - DirectorsTalk Interviews
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Play with 18.64% Upside Potential - DirectorsTalk Interviews
Chart based exit strategy for Rhythm Pharmaceuticals Inc.Weekly Investment Recap & Technical Pattern Based Signals - newser.com
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rhythm Pharmaceuticals Inc 주식 (RYTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shulman Joseph | Chief Technical Officer |
Sep 02 '25 |
Sale |
105.30 |
16,781 |
1,767,006 |
8,509 |
5.74%
자본화:
|
볼륨(24시간):